base seem reflect
rate cl ew market share challeng continu limit
cl top-line growth although see enhanc visibl
around ep re-bas includ greater
invest potenti rebound organ sale growth
ep re-bas ep cl stock slightli post
ep despit initi ep growth guidanc -msd y-o-
consensu attribut mute stock reaction solid org
sale growth ep re-bas larg anticip
market see mid-decemb note detail downsid ep risk mega-
cap stapl compani initi guidanc investor becom
interest de-risk ep outlook organ sale growth
expect improv behind price innov call cl stress
robust innov pipelin core busi includ colgat
total relaunch colgat total sf hill scienc diet relaunch new
sku us store global follow quarter cl also
highlight innov part portfolio expans
natur toothpast offer addit palmol person line
across latin america launch new bodi wash hand soap line
palmol europ well distribut expans newli
acquir pca skin elta md skincar brand innov help cl
take price two third price plan alreadi secur
either place pend innov cl plan support innov
increas brand-build activ in-stor display promot
higher advertis includ super bowl commerci estim midpoint
cl ep guidanc impli mid-teen y-o-i increas despit
improv top-line outlook aid price innov support
remain ew valuat ep re-rat time post
expect ep revis alreadi seem give cl credit top-line rebound
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit cl total compani em ltm organ sale
start stabil
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
despit increas drive pick organ sale growth
remain mute prefer pg post superior
org sale growth cl three straight quarter continu go
forward along greater forward recoveri price vs commod cost
gap yet pg still trade price-to-earnings discount cl
number cl ep cent on-consensu
estim although qualiti subpar gross oper margin
miss ep upsid driven lower expect tax rate ad
cent ep vs forecast cl organ sale growth unround
volum price ahead street account
consensu driven strong organ sale growth pet nutrit two-year
averag organ sale growth better
albeit still organ sale growth improv emerg
market acceler vs flat trend
report sale beat translat gross profit beat
gm bp consensu bp yoy higher sg vs
consensu bp yoy sale bp model
drove profit miss line lower expect tax rate
ad cent vs model result ep cent consensu
-msd y-o-i declin impli ep assum declin
base prior consensu previous
lsd cl provid initi organ sale growth guidanc y-o-i
increas flat lsd report basi improv vs
level driven price innov call cl indic expect
bp y-o-i gross margin increas benefit price cl
indic two-third expect price alreadi secur
product program offset increas raw materi cost cl expect
increas underli commod cost vs increas
impact transact fx estim midpoint cl ep guidanc
impli mid-teen increas behind cl product innov cl also
indic call expect tax rate
lower ep estim net post ep lower ep
estim primarili driven higher expect
reinvest pt move base ep
higher market/hpc group multipl valuat level impli price
target discount multipl appli pg given higher
growth outlook procter
base case scenario
organ top-line drive multipl expans bp volum upsid
share gain bp price upsid drive multipl expans
bull case ep impli ev/ebitda includ strateg
top-line growth rang forecast organ top-line growth
beyond appli price-to-earnings multipl ev/ebitda
discount target multipl pg given superior top-line
margin outlook procter gambl
sale growth deceler flattish rang secular us pressur drive bp
price downsid bp volum loss bp reinvest
spur top-line weak macro difficult competit environ drive
bp volum bp price invest intern appli
exhibit bear bull top-line upside/downsid driver cl multipl
valu
trend expect organ sale remain
mute growth cl
msd histor trend lt target
believ cl organ sale growth
emerg market return
histor level due heighten
competit local player competit
environ compani shift spend
secularli challeng us market
well lower inflationari price compar
last year
diminish strateg still
beliv cl advantag vs peer
greater mix higher growth emerg
market person care product
categori believ market
attribut lower strateg halo
histor given weaken
fundament compar histor trend
note knowledg
level premium household product
peer start look stretch
outlook cl diminish strateg halo
particularli believ cl price-to-earnings premium
pg look high consid better
top-line oper profit outlook pg
risk achiev price
market share payback ad spend
cost consolid potenti increas
downsid risk weaker price
market share loss local player
higher commod cost strateg
pt forecast organ sale growth go forward modestli
hpc peer led improv us result build market share momentum
better price realiz continu cost save support bp om expansion/yr
drive hsd ep growth appli multipl ep slight premium
pg average given acceler fundament
share vacil currenc commod volatil
